In vitro proteasome processing of neo-splicetopes does not predict their presentation in vivo
- Institute of Immunology (Charité - Universitätsmedizin Berlin) and German Cancer Research Center (DKFZ Heidelberg), Germany
- Institute of Biochemistry (Charité - Universitätsmedizin Berlin), Germany
- Max-Delbrück Center for Molecular Medicine, Germany
- Institut für Physiologie (Charité - Universitätsmedizin Berlin), Germany
- Max Delbrück Center for Molecular Medicine in Helmholtz Association, Germany
- Charité - Universitätsmedizin Berlin, Germany
Abstract
Proteasome catalyzed peptide splicing (PCPS) of cancer-driving antigens could generate attractive neoepitopes to be targeted by TCR-based adoptive T cell therapy. Based on a spliced peptide prediction algorithm TCRs were generated against putative KRASG12V and RAC2P29L derived neo-splicetopes with high HLA-A*02:01 binding affinity. TCRs generated in mice with a diverse human TCR repertoire specifically recognized the respective target peptides with high efficacy. However, we failed to detect any neo-splicetope specific T cell response when testing the in vivo neo-splicetope generation and obtained no experimental evidence that the putative KRASG12V- and RAC2P29L-derived neo-splicetopes were naturally processed and presented. Furthermore, only the putative RAC2P29L-derived neo-splicetopes was generated by in vitro PCPS. The experiments pose severe questions on the notion that available algorithms or the in vitro PCPS reaction reliably simulate in vivo splicing and argue against the general applicability of an algorithm-driven 'reverse immunology' pipeline for the identification of cancer-specific neo-splicetopes.
Data availability
Additional source data comprising databases for ProteomDiscoverer, Kras/RAC2 kinetics, cleavage maps and PD2.1 result files have been submitted to Dryad under DOI:10.5061/dryad.jq2bvq88b
-
Willimsky_et_al_11-08-2020-RA-eLife-62019_Supplementary data filesDryad Digital Repository, doi:10.5061/dryad.jq2bvq88b.
Article and author information
Author details
Funding
Deutsche Forschungsgemeinschaft (SFB-TR36)
- Gerald Willimsky
- Thomas Blankenstein
Deutsche Krebshilfe (111546)
- Gerald Willimsky
Berlin Institute of Health (CRG-1)
- Thomas Blankenstein
- Peter M Kloetzel
DKTK joint funding (NEO-ATT)
- Gerald Willimsky
Berliner Krebsgesellschaft
- Peter M Kloetzel
Helmholtz-Gemeinschaft, Zukunftsthema 'Immunology and Inflammation'
- Gerald Willimsky
- Thomas Blankenstein
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Ethics
Animal experimentation: All animal experiments were performed according to institutional and national guidelines and regulations. The experiments were approved by the governmental authority (Landesamt für Gesundheit und Soziales, Berlin, H0086/16).
Copyright
© 2021, Willimsky et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 2,004
- views
-
- 276
- downloads
-
- 13
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
In vitro proteasome processing of neo-splicetopes does not predict their presentation in vivo
eLife 10:e62019.
https://doi.org/10.7554/eLife.62019
